Cart
sales@molnova.com
Insulin degludec
CAS No. 844439-96-9
Insulin degludec ( —— )
Catalog No. M25046 CAS No. 844439-96-9
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 298 | In Stock |
|
| 10MG | 496 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameInsulin degludec
-
NoteResearch use only, not for human use.
-
Brief DescriptionInsulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.
-
DescriptionInsulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.Insulin degludec (0.001-1000 nM; 12 h) binds with insulin receptor with an IC50 value of 19.59 nM/L.Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells.
-
In VitroInsulin degludec (0.001-1000 nM; 12 h) binds with insulin receptor with an IC50 value of 19.59 nM.Insulin degludec (200 nM; 10 min) increases glucose uptake in HL-1 cells. Western Blot Analysis Cell Line:HL-1 cardiomyocytes Concentration:200 nM Incubation Time:0-60 min Result:Decreased the level of Akt phosphorylation after 5 and 10min treatment.
-
In VivoInsulin degludec (5 U/kg; s.c. once daily for 30 days) affects glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. Animal Model:Male Swiss mice with diabetes Dosage:5 U/kg Administration:Subcutaneous injection; 5 U/kg once daily for 30 days Result:Showed a fast response to insulin-induced hypoglycemia with a glycemic level at or slightly under 100 mg/dl after 60 min and this response effect can be abolished by cortisol. Diminished rates of glucose production and showed a low lactate production in livers. Increased the number of hepatocytes.
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetInsulin Receptor
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number844439-96-9
-
Formula Weight——
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility0.1 M HCL : 50 mg/mL (ultrasonic and adjust pH to 2 with 0.1 M HCL)
-
SMILESN/A
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bataglini C, et al. Insulin degludec and glutamine dipeptide modify glucose homeostasis and liver metabolism in diabetic mice undergoing insulin-induced hypoglycemia. J Appl Biomed. 2021 Dec;19(4):210-219.
2. Hartmann T, et al. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function. Cardiovasc Diabetol. 2016 Jul
molnova catalog
related products
-
Insulin degludec
Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM/L for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.
-
MSDC-0160
A new generation insulin sensitizer and mitochondrial target of thiazolidinediones (mTOT) modulator that has low affinity for binding and activation of PPARγ (EC50=23.7 uM).
-
Insulin Receptor 114...
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates.
